Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
35–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subjects who have completed the Treatment Period of clinical trial DAR-311
Receiving and adhering to full doses of appropriate guideline-recommended antihypertensive drugs from three different classes of antihypertensive agents, including a diuretic
You may not be if
Subjects who discontinued treatment with study drug prior to the end of the Treatment Period of DAR-311 due to a study drug-related adverse event (AE)
Treatment with another endothelin receptor antagonist within 6 months of study entry
Clareo Health | DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension
